Comparative Pharmacology
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus DIATRIZOATE 60.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus DIATRIZOATE 60.
CHOLOGRAFIN MEGLUMINE vs DIATRIZOATE-60
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholografin meglumine is an iodinated contrast agent that opacifies the biliary tract. It is actively taken up by hepatocytes and excreted into the bile, allowing radiographic visualization of the bile ducts and gallbladder.
Diatrizoate is an ionic, monomeric, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, enhancing radiographic imaging by attenuating X-ray beams. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
Intravenous: 20 mL (10.3 g) of a 52% solution (meglumine salt) administered by slow IV injection over 3-5 minutes; repeated once after 10-15 minutes if visualization is inadequate, not to exceed 40 mL total.
1-2 mL/kg IV bolus up to 150 mL total for contrast-enhanced CT; repeat doses may be given based on imaging needs.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic function, reflecting rapid biliary excretion; prolonged in hepatic impairment.
Terminal half-life approximately 1-2 hours in patients with normal renal function. Prolonged in renal impairment (up to 20-30 hours in anuria).
Primarily hepatic excretion via bile into feces; renal excretion accounts for <1% of the dose in patients with normal hepatic function.
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Negligible biliary or fecal elimination.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent